Manufacturing

Articles

Successful drug delivery via a dry powder inhaler is determined by the API physicochemical properties, the formulation composition and process, the device and operating conditions, the patient–device relationship, the environmental variables, and ultimately, patient compliance.

Developing an Orally Inhaled Dry Powder Formulation—A Complex Itinerary and a Technological Challenge

Jon Faulkes, formerly business development manager, formulation development, Aesica Pharmaceuticals

Emma J Mickley, PhD, vice-president, corporate business development, Aesica Pharmaceuticals

Advances in engineered particles and the subsequent reduction in the API mass required to achieve a therapeutic dose can lead to a reduction in side effects.

Fit for the Lung?

Mark Copley is Sales Director at Copley Scientific.

The role of add-on devices and how they affect drug delivery with a pressurized metered dose inhaler.

Exploring Newly Introduced Methods for Testing MDIs with Add-On Devices

Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.

Experts discuss factors affecting drug delivery to the lungs and key considerations when developing inhalation formulations.

Pulmonary Drug Delivery—Particle Engineering for Inhaled Therapeutics

Products enable testing in accordance with methods described in new USP monograph.

Copley Scientific Launches Two New Products for MDI Testing

In this sponsored podcast, Adam Stuart, Senior Design Engineer at 3M Drug Delivery Systems, discusses the role of dose counters for metered dose inhalers and the technical challenges companies can face when adding this feature to their inhaler products.

The Benefits and Challenges of Dose Counters for Metered Dose Inhalers

Intertek is now offering comprehensive services for the development of orally inhaled and intranasal drug products (OINDPs) for both small molecules and biologics.

Intertek Launches Comprehensive Inhalation Product Development Services

Bend Research adds powder-filling technology.

Bend Research Adds to Oral and Inhalation Capabilities

Adamis Pharmaceuticals agrees to license and potentially acquire 3M's Taper Dry Powder Inhaler technology.

Adamis Pharmaceuticals Licenses 3M's Dry Powder Inhaler Technology

Australian team develops method for making ultrafine particles for more efficient drug delivery.

Manufacturing, Inhalation Drugs